Health Care Contracts & Agreements
157,108 Contracts from 2,097 Health Care Companies
- Biotechnology (59,279 contracts from 663 companies)
- Health Care Equipment & Supplies (29,041 | 359)
- Health Care Providers & Services (25,999 | 476)
- Health Care Technology (4,931 | 71)
- Life Sciences Tools & Services (5,101 | 64)
- Pharmaceuticals (32,757 | 464)
- Form of Pre-Funded Warrant (Lirum Therapeutics, Inc., Filed With SEC on June 28, 2024)
- UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters (Lirum Therapeutics, Inc., Filed With SEC on June 28, 2024)
- Amended and Restated Employment Agreement, dated June 26, 2024, by and between MIRA Pharmaceuticals, Inc. and Michelle Yanez (MIRA PHARMACEUTICALS, INC., Filed With SEC on June 28, 2024)
- Amendment to Selected Product License Agreement (AB-201), dated September 6, 2023, by and between the Registrant and GC Cell Corporation (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Selected Product License Agreement (AB-201), dated September 29, 2020, by and between the Registrant and GC Cell Corporation (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Selected Product License Agreement (AB-101), dated November 21, 2019, by and between the Registrant and GC Cell Corporation (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Master Research Services Agreement, dated August 3, 2020, by and between the Registrant and GC Cell Corporation (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Amendment No. 1 to Master Agreement for Manufacturing Services, dated June 16, 2020, by and between the Registrant and GC Cell Corporation (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Master Agreement for Manufacturing Services, dated March 16, 2020, by and between the Registrant and GC Cell Corporation (f/k/a GC Lab Cell Corporation) (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Amendment No. 1 to Option and License Agreement, dated June 23, 2020, by and between the Registrant and GC Cell Corporation (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Option and License Agreement, dated September 4, 2019, by and between the Registrant and GC Cell Corporation (f/k/a GC Lab Cell Corporation) (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Office Lease, dated June 12, 2019, by and between the Registrant and AAT La Jolla Commons, LLC (as successor-in-interest to HSPFLa Jolla Commons I Investors LLC) (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Employment Offer Letter, dated August 27, 2020, as amended, by and between the Registrant and Jennifer Bush (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Employment Offer Letter, dated May 21, 2022, by and between the Registrant and Thorsten Graef, M.D., Ph.D (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Executive Employment Agreement, dated December 14, 2020, as amended, by and between the Registrant and Fred Aslan, M.D (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Artiva Biotherapeutics, Inc. 2024 Employee Stock Purchase Plan (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Artiva Biotherapeutics, Inc. 2024 Equity Incentive Plan (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Forms of Stock Option Grant Notice, Stock Option Grant Notice with Acceleration of Vesting, Option Agreement and Notice of Exercise under the Artiva Biotherapeutics, Inc. 2020... (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Artiva Biotherapeutics, Inc. 2020 Equity Incentive Plan, as amended (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Form of Indemnification Agreement by and between the Registrant and its directors and officers (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Amended and Restated Investors Rights Agreement, dated February 22, 2021, by and among the Registrant and certain of its stockholders (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Form of Common Stock Certificate (Artiva Biotherapeutics, Inc., Filed With SEC on June 28, 2024)
- Amendment to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan (Aligos Therapeutics, Inc., Filed With SEC on June 28, 2024)
- Form of Class D Warrant (Bluejay Diagnostics, Inc., Filed With SEC on June 28, 2024)
- Form of Class C Warrant (Bluejay Diagnostics, Inc., Filed With SEC on June 28, 2024)
- Form of Prefunded Warrant (Bluejay Diagnostics, Inc., Filed With SEC on June 28, 2024)
- Underwriting Agreement (Bluejay Diagnostics, Inc., Filed With SEC on June 28, 2024)
- Amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, effective as of June 27, 2024 (HELIUS MEDICAL TECHNOLOGIES, INC., Filed With SEC on June 28, 2024)
- Underwriting Agreement dated June 26, 2024 by and among the Company, BofA Securities, Inc. and Jefferies LLC, as representatives of the several Underwriters listed on Schedule A... (Addus HomeCare Corp, Filed With SEC on June 28, 2024)
- Form of Securities Purchase Agreement (Tonix Pharmaceuticals Holding Corp., Filed With SEC on June 28, 2024)
- Warrant Agent Agreement, dated June 28, 2024, between Tonix Pharmaceuticals Holding Corp. and VStock Transfer (Tonix Pharmaceuticals Holding Corp., Filed With SEC on June 28, 2024)
- Form of Pre-Funded Warrant (Tonix Pharmaceuticals Holding Corp., Filed With SEC on June 28, 2024)
- Placement Agency Agreement, dated June 27, 2024, between Tonix Pharmaceuticals Holding Corp. and Dawson James Securities Inc (Tonix Pharmaceuticals Holding Corp., Filed With SEC on June 28, 2024)
- Underwriting Agreement, dated June 27, 2024, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (Savara Inc, Filed With SEC on June 28, 2024)
- Warrant Amendment Agreement, dated June 27, 2024 (BRAINSTORM CELL THERAPEUTICS INC., Filed With SEC on June 28, 2024)
- Placement Agency Agreement, dated as of June 27, 2024 by and between the Company and the placement agent party thereto (BRAINSTORM CELL THERAPEUTICS INC., Filed With SEC on June 28, 2024)
- Form of Securities Purchase Agreement (BRAINSTORM CELL THERAPEUTICS INC., Filed With SEC on June 28, 2024)
- Form of Pre-Funded Warrant (BRAINSTORM CELL THERAPEUTICS INC., Filed With SEC on June 28, 2024)
